At Novartis, we are focused on improving the lives of the millions of people affected by respiratory and inflammation diseases and continue to research, develop and launch innovative therapies which treat chronic obstructive pulmonary disease, chronic spontaneous urticaria and severe allergic asthma.
The table below outlines our current research within respiratory and inflammation diseases:
Mechanism of action
Potential indication/ disease area
Route of administration
Planning filing dates
Anti-IgE monoclonal antibody
Chronic Spontaneous Urticaria
Indacaterol, mometasone furoate (in fixed-dose combination)
Long-acting beta2-agonist and inhaled corticosteroid
Indacaterol, mometasone furoate, glycopyrronium bromide (in fixed-dose combination)
Long-acting beta2 agonist, long-acting muscarinic antagonist and inhaled corticosteroid
Click on the conditions for more information about our work.
In the UK, conditions such as asthma are major public health issues and have a high impact on patients, on NHS resources and on the wider economy:
Asthma is one of the most common medical conditions in the UK affecting around 5.4 million people1
Each year, 12.7 million working days are reported as sickness absence as a result of asthma in the UK2
Asthma in the UK is expensive - the annual direct NHS healthcare expenditure on asthma in the UK is in excess of £1 billion3
One in five asthma patients report being concerned that their next asthma attack will kill them4
On average, three people die each day in the UK due to their asthma1
At Novartis, as well as furthering scientific research, we work to ensure people in need receive the most effective medicine for their condition as promptly as possible. Some of our work includes:
Organising training events for doctors and nurses which contribute to professional development in the area of severe allergic asthma
Working with hospital emergency and respiratory departments to conduct reviews and audits of their data on the intake of people with asthma exacerbations, with the aim of identifying and facilitating sharing of best practice
Supporting “real world” studies and collation of new data
Jackson, M. (2006). Allergy: The History of a Modern Malady. London: Reaktion Books Ltd.
Chronic spontaneous urticaria
Chronic spontaneous urticaria (CSU) is a distressing skin condition with no specific trigger. It presents as swollen, itchy and sometimes painful hives (wheals), and recurs daily or almost daily for at least 6 weeks.5-10
CSU can strike at any time. Everyday life can become frustrating and challenging – from maintaining relationships to being effective at work. In fact, nearly one quarter of people miss work at least once a month due to their condition, and 56% say they do not have control over their symptoms.5 In the UK, between 318,000 and 630,000 people may be affected by CSU.6,7 That’s approximately the population of Manchester (503,172).12
At Novartis our work looks to ensure people in need receive the most effective medicine for their condition as promptly as possible. Examples include:
Organising training events for doctors and nurses which contribute to professional development in the area of chronic spontaneous urticaria
Providing assistance to healthcare professionals in delivering treatment to patients
Supporting “real world” studies and collation of new data
Wheals of Despair market research amongst 103 patients. November 2013-January 2014
Sánchez-Borges M. Asero R, Asotegui IJ, et al. Diagnosis and treatment of angioedemia: a worldwide perspective (position paper).World Allergy Organization Journal.2012; 5:125-147
Maurer M et al. Allergy 2011; 66 (3): 317-330X
O'Donnell Bf et al. Br J Dermatol 1997; 136:197-201
Zuberbier T, Asero R, Bindslev-Jensen G et al. The EAACI/GA^2LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of urticaria: the 2013 revision and update. Allergy 2014;69:868-887
Office for National Statistics. 2011 UK Census: Population density, local authorities in the United Kingdom. Table QS102UK.
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a condition where airways become inflamed and air sacs within the lungs are damaged. COPD causes airways to become narrower and means people living with the condition experience breathing difficulties; this affects many aspects of day-to-day life.13
It's estimated that two million people in the UK are living with COPD but their condition is undiagnosed.14 As a result, they are unable to benefit from professional support to improve their quality of life.
COPD is a serious condition which kills 30,000 people a year in the UK, that’s just 5,000 less than the UK's biggest cancer killer, lung cancer.
Awareness of COPD and its devastating effects are relatively low in the UK.14
Many people think COPD can only affect smokers; however, up to 20 per cent of people with COPD have been affected by non-smoking-related causes.14
Novartis/Pfizer UK Alliance
Novartis is committed to addressing the unmet medical needs of people with COPD. We strive to improve the quality of life of those affected by the condition through the development of innovative medicines and devices; these help ensure patients benefit from the right treatment at the right time.
In 2014, Novartis started a collaboration with Pfizer UK Limited; - this enables Pfizer to market and promote our COPD medicines in the UK. Novartis continues to be responsible for the manufacture, sale and distribution of both medicines, in addition to regulatory, pharmacovigilance and medical information commitments. We also remain the registered license holder with the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA).
Both Novartis and Pfizer have extensive experience in respiratory medicine and are pleased to provide two effective therapies for the treatment of COPD. These help some of the estimated two million people living with the condition in the UK.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any suspected adverse reactions via the Yellow Card Scheme. See www.mhra.gov.uk/yellowcard for how to report side effects.